Skip to main content
N

NXgenPort

NxGen Port develops an implantable chemo-port catheter integrated with microchip and sensor technology for oncology patients. This device measures and reports physiological body functions in vivo to enable remote patient monitoring. The system delivers real-time data analytics to providers, facilitating early intervention for complications like infection or neutropenia.

Saint Paul, United StatesFounded 202010300+ followers
Updated 20 months ago

Funding

$4.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

MI
Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Cancer patients requiring chemo-ports face a high risk of infection and other complications, leading to hospitalizations and increased healthcare costs. Current monitoring methods often fail to detect early signs of physiological distress, resulting in delayed interventions and compromised patient outcomes. Existing solutions lack the ability to continuously and remotely monitor key physiological parameters in real-time.

Solution

NXgenPort is developing a digital health platform that integrates microchip and sensor technology with an implantable chemo-port catheter to enable remote, real-time physiological monitoring for cancer patients. The system measures and reports in-vivo data related to infection, cardiac function, blood cell counts, oxygen levels, body temperature, and cancer prevalence. This early detection system provides actionable data to healthcare providers, facilitating timely interventions and virtual patient management. By continuously monitoring key health indicators, NXgenPort aims to reduce hospitalizations, improve patient outcomes, and lower healthcare costs associated with complications. The platform also supports virtual clinical trials by enabling passive data collection for adherence and drug efficacy monitoring.

Target Audience

The primary target audience includes oncologists, hospitals, and healthcare providers who manage cancer patients with chemo-ports, as well as pharmaceutical companies conducting clinical trials.

Features

  • Implantable chemo-port catheter integrated with microchip and sensor technology
  • Remote, real-time monitoring of physiological parameters in vivo
  • Measures infection indicators, cardiac function, blood cell counts, oxygen levels, body temperature, and cancer prevalence
  • Digital health platform for data analytics and reporting
  • Early alerts to healthcare providers for timely intervention
  • Secure data transmission and storage
  • Virtual patient management capabilities
  • Support for virtual clinical trials with passive data collection
This profile is AI-generated and may contain inaccuracies.